Overexpression of apolipoprotein-B improves cardiac function and increases survival in mice with myocardial infarction

Biochemical and Biophysical Research Communications

Volumn 385, Issue 3, 2009, Pages 336-340

  Råmunddal, Truls ^a   Lindbom, Malin ^a   Scharin Täng, Margareta ^a   Stillemark Billton, Pia ^a   Boren, Jan ^a   Omerovic, Elmir ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Animal model; Cardioprotection; Heart failure; Ischemia reperfusion injury; Myocardial infarction; Myocardial lipid metabolism

Indexed keywords

APOLIPOPROTEIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; SYSTOLE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS B; HEART; HEART FAILURE; MALE; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 67349169101     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.053     Document Type: Article

References (19)

1. Nielsen L.B., Veniant M., Boren J., Raabe M., Wong J.S., Tam C., Flynn L., Vanni-Reyes T., Gunn M.D., Goldberg I.J., Hamilton R.L., and Young S.G. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 98 (1998) 13-16
2. Boren J., Veniant M.M., and Young S.G. Apo B100-containing lipoproteins are secreted by the heart. J. Clin. Invest. 101 (1998) 1197-1202
3. Yokoyama M., Yagyu H., Hu Y., Seo T., Hirata K., Homma S., and Goldberg I.J. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J. Biol. Chem. 279 (2004) 4204-4211
4. Linton M.F., Farese Jr. R.V., Chiesa G., Grass D.S., Chin P., Hammer R.E., Hobbs H.H., and Young S.G. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92 (1993) 3029-3037
5. Fisher S.G., and Marber M.S. An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heart. J. Pharmacol. Toxicol. Methods 48 (2002) 161-169
6. Kumar D., Hacker T.A., Buck J., Whitesell L.F., Kaji E.H., Douglas P.S., and Kamp T.J. Distinct mouse coronary anatomy and myocardial infarction consequent to ligation. Coron. Artery Dis. 16 (2005) 41-44
7. Salto-Tellez M., Yung Lim S., El-Oakley R.M., Tang T.P., ZA A.L., and Lim S.K. Myocardial infarction in the C57BL/6J mouse: a quantifiable and highly reproducible experimental model. Cardiovasc. Pathol. 13 (2004) 91-97
8. Selye H., Bajusz E., Grasso S., and Mendell P. Simple technique for the surgical occlusion of coronary vessels in the rat. Angiology 11 (1960) 398-407
9. Pollick C., Hale S.L., and Kloner R.A. Echocardiographic and cardiac Doppler assessment of mice. J. Am. Soc. Echocardiogr. 8 (1995) 602-610
10. Aurigemma G.P., Gaasch W.H., Villegas B., and Meyer T.E. Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. Curr. Probl. Cardiol. 20 (1995) 361-440
11. Nielsen L.B. Lipoprotein production by the heart: a novel pathway of triglyceride export from cardiomyocytes. Scand. J. Clin. Lab. Invest. Suppl. 237 (2002) 35-40
12. Bilheimer D.W., Buja L.M., Parkey R.W., Bonte F.J., and Willerson J.T. Fatty acid accumulation and abnormal lipid deposition in peripheral and border zones of experimental myocardial infarcts. J. Nucl. Med. 19 (1978) 276-283
13. Mancuso D.J., Abendschein D.R., Jenkins C.M., Han X., Saffitz J.E., Schuessler R.B., and Gross R.W. Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice. rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition. J. Biol. Chem. 278 (2003) 22231-22236
14. Curtis M.J., Pugsley M.K., and Walker M.J. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc. Res. 27 (1993) 703-719
15. van der Vusse G.J., Glatz J.F., Stam H.C., and Reneman R.S. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol. Rev. 72 (1992) 881-940
16. Corr P.B., Yamada K.A., Creer M.H., Sharma A.D., and Sobel B.E. Lysophosphoglycerides and ventricular fibrillation early after onset of ischemia. J. Mol. Cell. Cardiol. 19 Suppl 5 (1987) 45-53
17. London B. Cardiac Arrhythmias: from (transgenic) mice to men. J. Cardiovasc. Electrophysiol. 12 (2001) 1089-1091
18. Wit A.L., and Janse M.J. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation 85 (1992) I32-142
19. Avramoglu R.K., and Adeli K. Hepatic regulation of apolipoprotein B. Rev. Endocr. Metab. Disord. 5 (2004) 293-301